首页> 美国卫生研究院文献>Journal of Clinical Oncology >Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

【2h】

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

机译：细胞毒性化疗失败后转移性胰腺神经内分泌肿瘤患者的每日口服依维莫司活性：II期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

PurposeNo established treatment exists for pancreatic neuroendocrine tumor (NET) progression after failure of chemotherapy. Everolimus (RAD001), an oral inhibitor of mammalian target of rapamycin, in combination with octreotide has demonstrated encouraging antitumor activity in patients with NETs.

机译：目的尚无针对化疗失败后胰腺神经内分泌肿瘤（NET）进展的既定治疗方法。 Everolimus（RAD001）是雷帕霉素哺乳动物靶标的口服抑制剂，与奥曲肽联用已证明对NETs具有令人鼓舞的抗肿瘤活性。

著录项

期刊名称 Journal of Clinical Oncology
作者
James C. Yao; Catherine Lombard-Bohas; Eric Baudin; Larry K. Kvols; Philippe Rougier; Philippe Ruszniewski; Sakina Hoosen; Jessica St. Peter; Tomas Haas; David Lebwohl; Eric Van Cutsem; Matthew H. Kulke; Timothy J. Hobday; Thomas M. ODorisio; Manisha H. Shah; Guillaume Cadiot; Gabriele Luppi; James A. Posey; Bertram Wiedenmann;
展开▼
作者单位

展开▼
年(卷),期 -1(28),1
年度 -1
页码 69–76
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. [J] . Yao JC, Lombard Bohas C, Baudin Journal of Clinical Oncology . 2010,第1期

机译：细胞毒性化疗失败后转移性胰腺神经内分泌肿瘤患者的每日口服依维莫司活性：II期试验。
3. 6514 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial [J] . A.Cherfi, J.Yao, M.Pavel, European Journal of Cancer Supplements . 2009,第2期

机译：6514细胞毒性化疗失败后转移性胰腺神经内分泌肿瘤患者的每日口服依维莫司活性：II期试验
4. 6514 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial [J] . A.Cherfi, J.Yao, M.Pavel, European Journal of Cancer Supplements . 2009,第2期

机译：6514细胞毒性化疗失败后转移性胰腺神经内分泌肿瘤患者的每日口服依维莫司活性：II期试验
5. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
6. ISL-1 Expression as a Potential Prognostic Factor in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors [D] . Assi, Hussein. 2020

机译：ISL-1表达作为具有良好分化的胰腺神经内分泌肿瘤患者的潜在预后因素
7. A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Trial (RADIANT-3) of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: Updated Safety and Overall Survival Results [O] . Jonathan R. Strosberg, James C. Yao 2012

机译：晚期胰腺神经内分泌肿瘤患者中依维莫司的一项随机双盲安慰剂对照多中心III期试验（RADIANT-3）：更新的安全性和总体生存结果
8. A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial) [O] . Hiroyuki Okuyama, Masafumi Ikeda, Takuji Okusaka, 2020

机译：高级胰腺神经内分泌癌耐火或不耐受铂化疗（Nector试验）患者血尿症患者的II期试验

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅